Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Rhea-AI Summary

Vir Biotechnology, Inc. (NASDAQ:VIR) has announced that Mark Eisner, M.D., M.P.H., Executive Vice President and Chief Medical Officer, will participate in a fireside chat at the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference. The event is scheduled for Tuesday, October 8, at 10:00 a.m. PT / 1:00 p.m. ET.

A live webcast of the fireside chat will be available under the Events & Presentations section in the Investors area of the Vir website at www.vir.bio. The webcast will remain archived on the site for 30 days following the event.

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that Mark Eisner, M.D., M.P.H., Executive Vice President and Chief Medical Officer, is scheduled to participate in a fireside chat at the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference on Tuesday, October 8, at 10:00 a.m. PT / 1:00 p.m. ET.

A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days.

About Vir Biotechnology, Inc.

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Vir’s clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections, in addition to multiple oncology programs. Vir also has a preclinical portfolio of programs across a range of other infectious diseases and oncologic malignancies. Vir routinely posts information that may be important to investors on its website.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241003019939/en/

Media

Arran Attridge

Senior Vice President, Corporate Communications

aattridge@vir.bio

Investors

Richard Lepke

Senior Director, Investor Relations

rlepke@vir.bio

Source: Vir Biotechnology, Inc.

FAQ

When is Vir Biotechnology (VIR) participating in the H.C. Wainwright Viral Hepatitis Conference?

Vir Biotechnology (VIR) is participating in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference on Tuesday, October 8, at 10:00 a.m. PT / 1:00 p.m. ET.

Who will represent Vir Biotechnology (VIR) at the H.C. Wainwright conference?

Mark Eisner, M.D., M.P.H., Executive Vice President and Chief Medical Officer of Vir Biotechnology, will represent the company at the conference.

How can investors access Vir Biotechnology's (VIR) fireside chat at the conference?

Investors can access a live webcast of the fireside chat under the Events & Presentations section in the Investors area of Vir Biotechnology's website at www.vir.bio.

How long will the webcast of Vir Biotechnology's (VIR) fireside chat be available?

The webcast of Vir Biotechnology's (VIR) fireside chat will be archived on their website for 30 days following the event.